Aeglea BioTherapeutics, Inc (AGLE)

Etorro trading 970x250
Aeglea BioTherapeutics, Inc (AGLE) Logo

About Aeglea BioTherapeutics, Inc

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company’s lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company’s preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas. Address: 805 Las Cimas Parkway, Austin, TX, United States, 78746

Aeglea BioTherapeutics, Inc News and around…

Latest news about Aeglea BioTherapeutics, Inc (AGLE) common stock and company :

Sum Up The Parts: IEIH Could Be Worth $42
11 Jan, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.

Aeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022
05 Jan, 2022 Yahoo! Finance

Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in two investor conferences as follows:

3 Biotech Stocks That Sank: Are Any a Bad-News Buy?
17 Dec, 2021 FinancialContent

At least one of the three could be in store for better news in the future.

Tuesday 12/14 Insider Buying Report: EVRG, AGLE
14 Dec, 2021 FinancialContent

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.

Aeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $198,982 of Shares
14 Dec, 2021 Yahoo! Finance

President & CEO of Aeglea Biotherapeutics Inc (30-Year Financial, Insider Trades) Anthony G. Quinn (insider trades) bought 53,634 shares of AGLE on 12/10/2021 at an average price of $3.71 a share.

What You Need To Know About Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) Investor Composition
12 Dec, 2021 Yahoo! Finance

If you want to know who really controls Aeglea BioTherapeutics, Inc. ( NASDAQ:AGLE ), then you'll have to look at the...

Sum Up The Parts: Russell 2000 Has 37% Upside
08 Dec, 2021 FinancialContent

The financial media loves to get predictions from experts about where they think a given stock market index is headed. Some experts look at technical analysis patterns, others look at valuation metrics, others apply a broad macro view of the economy..

60 Biggest Movers From Yesterday
07 Dec, 2021 FinancialContent

Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 200.4% to close at $15.05 on Monday after the company announced the ...

Mid-Afternoon Market Update: Dow Jumps 700 Points; Del Taco Restaurants Shares Spike Higher
06 Dec, 2021 FinancialContent

Toward the end of trading Monday, the Dow traded up 2.11% to 35,308.84 while the NASDAQ rose 1.24% to 15,272.25. The S&P also rose, ...

Why Aeglea BioTherapeutics Stock Is Way Down Today
06 Dec, 2021 FinancialContent

MIxed phase 3 clinical trial results are making investors nervous.

12 Health Care Stocks Moving In Monday's Intraday Session
06 Dec, 2021 FinancialContent

Gainers Adicet Bio (NASDAQ:ACET) shares increased by 42.08% to $13.92 during Monday's regular session. Adicet Bio's stock is trading ...

Mid-Day Market Update: Crude Oil Rises 3%; Aeglea BioTherapeutics Shares Plunge
06 Dec, 2021 FinancialContent

Midway through trading Monday, the Dow traded up 1.94% to 35,251.31 while the NASDAQ rose 0.55% to 15,168.35. The S&P also rose, ...

36 Stocks Moving In Monday's Mid-Day Session
06 Dec, 2021 FinancialContent

Gainers Del Taco Restaurants, Inc. (NASDAQ: TACO) shares jumped 64.6% to $12.40. Jack In The Box Inc (NASDAQ: JACK) agreed to ...

Mid-Morning Market Update: Markets Mostly Higher; Science Applications International Posts Upbeat Earnings
06 Dec, 2021 FinancialContent

Following the market opening Monday, the Dow traded up 1.35% to 35,048.01 while the NASDAQ fell 0.17% to 15,059.43. The S&P also ...

Why Did Aeglea BioTherapeutics Shares Nosedived To 52-Week Low On Monday Premarket?
06 Dec, 2021 FinancialContent

Aeglea BioTherapeutics Inc(NASDAQ: AGLE) has announced data from the Phase 3 study of pegzilarginase in Arginase 1 Deficiency ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
06 Dec, 2021 FinancialContent

Gainers Adicet Bio (NASDAQ:ACET) stock increased by 37.85% to $13.51 during Monday's pre-market session. The market ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
06 Dec, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader! We're starting off another busy week with a look at the biggest pre-market stock movers for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency
06 Dec, 2021 Yahoo! Finance

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the pivotal Phase 3 study, PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints), met the primary endpoint with a statistically significant reduction in plasma arginine from baseline after 24 weeks of treatment with pegzilarginase (p

Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency
05 Dec, 2021 Yahoo! Finance

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that it will host an investor conference call and webcast tomorrow morning to discuss the topline results from the PEACE Phase 3 clinical trial of pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D).

Bag This Bargain Even Cheaper Than Chief Financial Officer Alspaugh Did
18 Nov, 2021 FinancialContent

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on August 18, Aeglea BioTherapeutics Inc's Chief Financial Officer, Jonathan Alspaugh, invested $262,659.81 into 40,372 shares of AGLE, for a cost per share of $6.51..

Aeglea BioTherapeutics Appoints Hunter C. Smith to Board of Directors
16 Nov, 2021 Yahoo! Finance

Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Hunter C. Smith to its board of directors. Mr. Smith currently serves as the chief financial officer of Rhythm Pharmaceuticals.

Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Tops Revenue Estimates
04 Nov, 2021 Yahoo! Finance

Aeglea (AGLE) delivered earnings and revenue surprises of -6.90% and 1.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights
04 Nov, 2021 Yahoo! Finance

Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the third quarter ended September 30, 2021, and reviewed recent corporate updates and program highlights.

Aeglea BioTherapeutics Announces Presentation of Seven Abstracts at ICIEM 2021 Including Oral Presentation of PEACE Study Baseline Characteristics
04 Nov, 2021 Yahoo! Finance

Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that seven abstracts will be presented at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) 2021 being held November 21-23, 2021. The series of abstracts illustrate the building interest and knowledge around the clinical impact of Arginase 1 Deficiency (ARG1-D), the importa

Noteworthy Thursday Option Activity: AGLE, ZNGA, PZZA
21 Oct, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Aeglea BioTherapeutics Inc (AGLE), where a total volume of 538 contracts has been traded thus far today, a contract volume which is representative of approximately 53,800 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 52% of AGLE's average daily trading volume over the past month, of 103,485 shares..

Aeglea BioTherapeutics (NASDAQ:AGLE) shareholders have earned a 4.5% CAGR over the last five years
19 Oct, 2021 Yahoo! Finance

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...

Implied IEIH Analyst Target Price: $43
08 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.

Top Buys by Top Brass: Chief Financial Officer Alspaugh's $262.7K Bet on AGLE
03 Sep, 2021 FinancialContent

A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

Aeglea BioTherapeutics to Participate in Multiple Conferences in September 2021
01 Sep, 2021 Yahoo! Finance

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in the following medical and investor conferences:

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
13 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Aeglea BioTherapeutics, Inc (AGLE) is a NASDAQ Common Stock listed in , ,

970x250